Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001232108 | SCV001404654 | likely benign | Bardet-Biedl syndrome; McKusick-Kaufman syndrome | 2024-11-21 | criteria provided, single submitter | clinical testing | |
New York Genome Center | RCV002468200 | SCV002764452 | uncertain significance | McKusick-Kaufman syndrome; Bardet-Biedl syndrome 6 | 2021-11-05 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002468200 | SCV002784936 | uncertain significance | McKusick-Kaufman syndrome; Bardet-Biedl syndrome 6 | 2024-04-16 | criteria provided, single submitter | clinical testing | |
Breakthrough Genomics, |
RCV004695239 | SCV005194876 | uncertain significance | not provided | criteria provided, single submitter | not provided | ||
Prevention |
RCV004538487 | SCV004719376 | uncertain significance | MKKS-related disorder | 2024-09-24 | no assertion criteria provided | clinical testing | The MKKS c.1098T>A variant is predicted to result in the amino acid substitution p.Asn366Lys. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.076% of alleles in individuals of African descent in gnomAD, which may be too common to be an unreported primary cause of disease. Although we suspect this variant may possibly be benign, at this time its clinical significance is uncertain due to the absence of conclusive functional and genetic evidence. |